文献速递腹部技术与安全PET

68Ga-FAPI与18F-FDG PET/CT在胃癌转移检出与分期迁移中的比较

Comparison of 68Ga-FAPI PET/CT and 18F-FDG PET/CT in gastric cancer: impact on metastatic detection and stage migration.
PubMed 文献 · Br J Radiol · 2026-01-01

回顾性分析52例经病理证实的胃癌患者,均接受18F-FDG PET/CT与68Ga-FAPI PET/CT检查,比较两种显像对原发灶、转移灶及肿瘤分期的评估。结果显示68Ga-FAPI PET/CT原发灶摄取更高,腹膜转移检出率显著提高,25.0%的患者发生分期迁移,主要由于新检出转移灶导致分期上调。

要点

  • 68Ga-FAPI PET/CT较18F-FDG PET/CT提高腹膜转移检出率(30.8%对13.5%,P=.004)。
  • 两种显像间25.0%的患者发生分期迁移,以新检出转移导致的上调为主。
  • 印戒细胞癌中18F-FDG摄取偏低,而FAPI摄取受组织学亚型影响较小。

核心结论

  • 68Ga-FAPI PET/CT较18F-FDG PET/CT可改善胃癌转移性病变检出,尤其腹膜受累,有助于更准确分期。

研究设计与样本

  • 回顾性研究,纳入52例经病理确诊的胃癌患者,均接受18F-FDG PET/CT与68Ga-FAPI PET/CT检查。
  • 评估两种显像对原发灶摄取、转移累及范围和肿瘤分期,比较淋巴结、腹膜、肝、骨转移检出率及诊断效能。
  • 定量参数分析包括标准化摄取值(SUV)和肿瘤背景比(TBR)。

关键影像表现/征象

  • 68Ga-FAPI PET/CT原发灶摄取显著高于18F-FDG PET/CT(P<.001)。
  • 68Ga-FAPI PET/CT腹膜转移检出率为30.8%(16/52),18F-FDG PET/CT为13.5%(7/52)(P=.004)。
  • 68Ga-FAPI PET/CT淋巴结转移检出频率更高。
  • 两种显像肝转移诊断效能均较高。
  • 68Ga-FAPI PET/CT骨病变敏感性略高,18F-FDG PET/CT特异性略高。

诊断标准与关键数值

  • 原发灶摄取:68Ga-FAPI PET/CT显著高于18F-FDG PET/CT(P<.001)。
  • 腹膜转移检出率:68Ga-FAPI PET/CT为30.8%(16/52),18F-FDG PET/CT为13.5%(7/52),P=.004。
  • 肝转移:两种显像均显示较高的诊断性能。
  • 骨病变:68Ga-FAPI PET/CT敏感性略高,18F-FDG PET/CT特异性略高。
  • 分期迁移:两种显像间总分期迁移率为25.0%(13/52),主要归因于新检出转移灶导致的分期上调。

临床应用与阅片要点

  • 对可疑腹膜转移或分期不明确的胃癌患者,68Ga-FAPI PET/CT可能提供额外的转移检出价值。
  • 印戒细胞癌18F-FDG摄取偏低时,可考虑68Ga-FAPI PET/CT作为补充以减少漏诊。
  • 68Ga-FAPI PET/CT检出更多转移灶可能导致分期上调,建议在报告中注明其潜在的治疗决策影响。

局限性

  • 单中心回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To compare the diagnostic performance of 18F-fluorodeoxyglucose (18F-FDG) PET/CT and ⁶⁸Ga-FAPI PET/CT in patients with gastric cancer, with particular emphasis on metastatic detection and stage migration.

METHODS: Fifty-two patients with histopathologically confirmed gastric cancer who underwent both 18F-FDG PET/CT and ⁶⁸Ga-FAPI PET/CT were retrospectively analyzed. Primary tumor uptake, metastatic involvement, and tumor staging were evaluated for each modality. Detection rates for lymph node, peritoneal, liver, and bone metastases were compared. Diagnostic performance and stage migration between modalities were assessed. Quantitative parameters including standardized uptake value and tumor-to-background ratio were analyzed.

RESULTS: ⁶⁸Ga-FAPI PET/CT demonstrated significantly higher uptake in primary tumors compared with 18F-FDG PET/CT (P < .001). Peritoneal metastases were detected in 30.8% (16/52) of patients on ⁶⁸Ga-FAPI PET/CT compared with 13.5% (7/52) on 18F-FDG PET/CT (P = .004). Nodal metastases were also identified more frequently with ⁶⁸Ga-FAPI PET/CT. Both modalities showed high diagnostic performance for liver metastases, while ⁶⁸Ga-FAPI PET/CT demonstrated slightly higher sensitivity for bone lesions and 18F-FDG PET/CT showed slightly higher specificity. Overall stage migration between the 2 modalities occurred in 25.0% (13/52) of patients, predominantly due to upstaging associated with newly detected metastatic disease. In subgroup analysis, 18F-FDG uptake tended to be lower in signet-ring cell carcinoma, whereas FAPI uptake appeared less influenced by histological subtype.

CONCLUSION: : ⁶⁸Ga-FAPI PET/CT improves detection of metastatic disease, particularly peritoneal involvement, compared with 18F-FDG PET/CT in patients with gastric cancer and may contribute to more accurate disease staging.

ADVANCES IN KNOWLEDGE: This study highlights the added value of 68Ga-FAPI PET/CT in identifying metastatic disease and altering clinical staging, particularly through improved detection of peritoneal involvement, which may impact treatment decision-making.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Okuyan, Elboga, Sahin, et al. Comparison of 68Ga-FAPI PET/CT and 18F-FDG PET/CT in gastric cancer: impact on metastatic detection and stage migration. Br J Radiol. 2026. PMID: 42599242. doi:10.1093/bjr/tqag185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。